ASO-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice

被引：0
|
作者：
Tasfaout, H. [1 ]
Buono, S. [1 ]
Guo, S. [2 ]
Kretz, C. [1 ]
Monia, B. [2 ]
Cowling, B. [1 ]
Laporte, J. [1 ]
机构：
[1] IGBMC, Illkirch Graffenstaden, France
[2] Ionis Pharmaceut, Carlsbad, CA USA
来源：
NEUROMUSCULAR DISORDERS | 2016年 / 26卷
关键词：
D O I：
10.1016/j.nmd.2016.06.448
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
T.O.14
引用
收藏
页码：S209 / S210
页数：2
相关论文
共 50 条
  • [1] ASO-mediated Dnm2 knockdown prevents and reverts Myotubular myopathy in vivo in mice
    Tasfaout, H.
    Buono, S.
    Guo, S.
    Kretz, C.
    Monia, B.
    Laporte, J.
    Cowling, B. S.
    HUMAN GENE THERAPY, 2016, 27 (11) : A44 - A44
  • [2] Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice
    不详
    CHIMICA OGGI-CHEMISTRY TODAY, 2018, 36 (02) : 48 - 49
  • [3] Antisense Oligonucleotide-Mediated Dnm2 Knockdown Prevents and Reverts Myotubular Myopathy in Mice
    Tasfaout, Hichem
    MOLECULAR THERAPY, 2017, 25 (05) : 230 - 230
  • [4] Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice
    Tasfaout, Hichem
    Buono, Suzie
    Guo, Shuling
    Kretz, Christine
    Messaddeq, Nadia
    Booten, Sheri
    Greenlee, Sarah
    Monia, Brett P.
    Cowling, Belinda S.
    Laporte, Jocelyn
    NATURE COMMUNICATIONS, 2017, 8
  • [5] Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice
    Hichem Tasfaout
    Suzie Buono
    Shuling Guo
    Christine Kretz
    Nadia Messaddeq
    Sheri Booten
    Sarah Greenlee
    Brett P. Monia
    Belinda S. Cowling
    Jocelyn Laporte
    Nature Communications, 8
  • [6] ASO-mediated Dnm2 knockdown ameliorates the centronuclear myopathy phenotype of Dnm2RW/+ mice in a dose-dependent manner after disease onset
    Depla, M.
    Robe, A.
    Buono, S.
    Koch, C.
    Bitoun, M.
    Colombo, S.
    Cowling, B.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S58 - S58
  • [7] Antisense oligonucleotide-mediated Dnm2 knockdown delays myotubular myopathy in mice after a single injection
    Buono, S.
    Kretz, C.
    Koch, C.
    Robe, A.
    Guo, S.
    Monia, B.
    Laporte, J.
    Thielemans, L.
    Cowling, B.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S174 - S174
  • [8] Myostatin as a novel blood based biomarker for antisense oligonucleotide-mediated Dnm2 knockdown to treat myotubular myopathy in mice
    Buono, S.
    Koch, C.
    Robe, A.
    Kretz, C.
    Oca, R. Gomez
    Guo, S.
    Depla, M.
    Monia, B.
    Laporte, J.
    Thielemans, L.
    Cowling, B.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S72 - S72
  • [9] Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice
    Tasfaout, Hichem
    Lionello, Valentina M.
    Kretz, Christine
    Koebel, Pascale
    Messaddeq, Nadia
    Bitz, Deborah
    Laporte, Jocelyn
    Cowling, Belinda S.
    MOLECULAR THERAPY, 2018, 26 (04) : 1082 - 1092
  • [10] Skeletal muscle reduction of Dnm2 with antisense oligonucleotides in myotubular myopathy
    Buono, S.
    Robe, A.
    Oca, R. Gomez
    Koch, C.
    Guo, S.
    Depla, M.
    Monia, B.
    Laporte, J.
    Thielemans, L.
    Cowling, B.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S78 - S79
12345